European Union - Latvian - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - imunoloģisks aves - cālis - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

European Union - Latvian - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - cālis - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

European Union - Latvian - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - cūkas - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

European Union - Latvian - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - cūkas - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

Latvia - Latvian - Zāļu valsts aģentūra

beximco pharma uk ltd., united kingdom - atorvastatīns - apvalkotās tabletes - 10 mg

Latvia - Latvian - Zāļu valsts aģentūra

beximco pharma uk ltd., united kingdom - atorvastatīns - apvalkotās tabletes - 20 mg

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - oksikodona hidrohlorīds - ilgstošās darbības tablete - 10 mg

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - oksikodona hidrohlorīds - ilgstošās darbības tablete - 80 mg

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - oksikodona hidrohlorīds - ilgstošās darbības tablete - 5 mg

Latvia - Latvian - Zāļu valsts aģentūra

g.l. pharma gmbh, austria - oksikodona hidrohlorīds - ilgstošās darbības tablete - 20 mg